MARKET

CALA

CALA

Calithera Biosciences Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.1971
+0.0012
+0.61%
After Hours: 0.1954 -0.0017 -0.86% 19:32 05/26 EDT
OPEN
0.1959
PREV CLOSE
0.1959
HIGH
0.2070
LOW
0.1892
VOLUME
4.71M
TURNOVER
0
52 WEEK HIGH
2.593
52 WEEK LOW
0.1545
MARKET CAP
19.17M
P/E (TTM)
-0.1366
1D
5D
1M
3M
1Y
5Y
Short Volatility Alert: Calithera Biosciences
On Tuesday, shares of Calithera Biosciences (NASDAQ: CALA) experienced volatile short activity. After the activity, the stock price went up 1.95% to $0.2192.  The overall sentiment for CALA has been Bullish.
Benzinga · 05/18 16:26
Calithera to Present at the H.C. Wainwright Global Investment Conference
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder, president and chie...
GlobeNewswire · 05/17 11:00
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 05/16 12:16
30 Stocks Moving in Monday's Pre-Market Session
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) rose 25.2% to $2.09 in pre-market trading after gaining around 10% on Friday.
Benzinga · 05/16 10:57
110 Biggest Movers From Friday
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 154.9% to close at $0.51. ShiftPixy reported board approval special dividend to shareholders in form of common shares of Industrial Human Capital.
Benzinga · 05/16 09:23
23 Stocks Moving in Friday's Pre-Market Session
Gainers OTR Acquisition Corp. (NASDAQ: OTRA) rose 88.7% to $18.21 in pre-market trading after filing on Thursday showed shareholders approved merger with Comera Life Sciences.
Benzinga · 05/13 11:52
Calithera Biosciences stock slips after PT cut at Ladenburg
Calithera Biosciences (NASDAQ:CALA) stock plunges after Ladenburg analyst Aydin Huseynov lowered the price target to $1.50 from $3 and maintains a Buy rating on the shares after its Q1 results. The company
Seekingalpha · 05/11 16:57
Calithera Biosciences GAAP EPS of -$0.18 in-line
Calithera Biosciences press release (NASDAQ:CALA): Q1 GAAP EPS of -$0.18 in-line. Net loss for the three months ended March 31, 2022 was $13.8 million. Cash and cash equivalents totaled $44.7
Seekingalpha · 05/10 20:20
More
No Data
Learn about the latest financial forecast of CALA. Analyze the recent business situations of Calithera Biosciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

60.00%Strong Buy
0.00%Buy
40.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average CALA stock price target is 1.750 with a high estimate of 2.000 and a low estimate of 1.500.
High2.000
Average1.750
Low1.500
Current 0.1971
EPS
Actual
Estimate
-0.19-0.14-0.10-0.05
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 116
Institutional Holdings: 52.23M
% Owned: 53.71%
Shares Outstanding: 97.24M
TypeInstitutionsShares
Increased
19
9.48M
New
10
979.84K
Decreased
17
9.27M
Sold Out
18
3.41M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
+0.31%
Pharmaceuticals & Medical Research
+0.43%
Key Executives
President/Chief Executive Officer/Co-Founder/Director
Susan Molineaux
Chief Financial Officer/Secretary/IR Contact Officer
Stephanie Wong
Senior Vice President
Christopher Molineaux
Senior Vice President
Francesco Parlati
Senior Vice President
Eric Sjogren
Other
Emil Kuriakose
Lead Director/Independent Director
Deepa Pakianathan
Director
Keith Orford
Independent Director
Sunil Agarwal
Independent Director
Jonathan Drachman
Independent Director
Scott Garland
Independent Director
Suzy Jones
Independent Director
Blake Wise
Independent Director
H. Ward Wolff
No Data
No Data
About CALA
Calithera Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company’s is engaged in discovering and development of targeted therapies, which disrupt cellular metabolic pathways to preferentially block tumor cells and enhance immune-cell activity. The Company is advancing a pipeline of first-in-clinic, oral therapeutics to meaningfully expand treatment options available to patients. The Company’s principal operations are based in South San Francisco, California. It has a range of pipeline of small molecule drug candidates, which target enzymes controlling metabolically critical pathways in tumor cells and immune cells. It has multiple internally discovered clinical stage compounds that are all enzyme inhibitors. The Company is engaged in developing telaglenastat in combination with standard therapies in a select set of solid tumors. Its lead development pathway for telaglenastat is for the treatment of KEAP1 or NRF2 mutated non-small cell lung cancer (NSCLC).

Webull offers kinds of Calithera Biosciences Inc stock information, including NASDAQ:CALA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CALA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CALA stock methods without spending real money on the virtual paper trading platform.